HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care

被引：0

作者：

Yeung, Ka-Kit David ^{[1
]}

Crook, Juanita ^{[1
]}

Arbour, Gregory ^{[2
]}

Araujo, Cynthia ^{[1
]}

Batchelar, Deidre ^{[1
]}

Kim, David ^{[1
]}

Petrik, David ^{[1
]}

Rose, Tracey ^{[1
]}

Bachand, Francois ^{[1
]}

机构：

[1] BC Canc Kelowna, Kelowna, BC, Canada

[2] Univ British Columbia, Kelowna, BC, Canada

来源：

BRACHYTHERAPY | 2025年 / 24卷 / 02期

关键词：

Prostate cancer; Radiotherapy; High dose rate brachytherapy; DOSE-RATE BRACHYTHERAPY; ANDROGEN DEPRIVATION THERAPY; PATIENT-REPORTED OUTCOMES; RADIATION-THERAPY; CONFORMAL RADIOTHERAPY; TUMOR-CONTROL; INTERMEDIATE; BOOST; ESCALATION; SURVIVAL;

D O I：

10.1016/j.brachy.2024.12.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE: High dose rate (HDR) brachytherapy is increasingly adopted for dose escalation in prostate cancer treatment. We report the clinical efficacy and toxicity of HDR prostate brachytherapy combined with external beam radiotherapy (EBRT) and evaluate the predictability of the biochemical definition of cure of 4-year PSA <= 0.2 ng/mL for failure free survival (FFS). METHODS: A single centre retrospective study was conducted, including all patients with high- tier intermediate risk and high-risk prostate cancer treated with HDR brachytherapy combined with EBRT from 2011 to 2019. Patient and prostate cancer characteristics, treatment, clinical endpoints, and follow up were collected. RESULTS: Total 319 patients were analyzed. The median age was 68 with median follow up of 77.1 months. Total 142 had high-tier intermediate and 177 had high-risk disease. Brachytherapy doses were initially 20 Gy/2 fractions, and subsequently 15 Gy/1 fraction. All patients received 46 Gy/23 fractions of EBRT. Overall survival at 5 and 9 years was 92.2% and 77.0%, respectively. Failure-free survival (FFS) was 86.0% at 5 years and 76.1% at 9 years. PSA <= 0.2 ng/mL at 4 years was seen in 79.3% of patients and was associated with FFS of 94.1% at 9 years. Grade 3 urethral stricture, hematuria, or proctitis occurred in 2.8%, 0%, and 0%, respectively. CONCLUSION: HDR brachytherapy in addition to EBRT is effective treatment for unfavourable localized prostate cancer with a very acceptable toxicity profile. The biochemical definition of cure of PSA < 0.2 ng/mL at 4 years was predictive for FFS at 9 years. (c) 2025 The Authors. Published by Elsevier Inc. on behalf of American Brachytherapy Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

引用

页码：318 / 327

页数：10

共 39 条

[1] Eastham J.A., Boorjian S.A., Kirkby E., Clinically localized prostate cancer: AUA/ASTRO guideline, J Urol, 208, pp. 505-507, (2022)
[2] Dearnaley D.P., Jovic G., Syndikus I., Et al., Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial, Lancet Oncol, 15, pp. 464-473, (2014)
[3] Zietman A.L., DeSilvio M.L., Slater J.D., Et al., Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial, JAMA, 294, pp. 1233-1239, (2005)
[4] Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., Et al., Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 gy of radiotherapy with 78 gy, J Clin Oncol, 24, pp. 1990-1996, (2006)
[5] Astrom L., Pedersen D., Mercke C., Et al., Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer, Radiother Oncol, 74, pp. 157-161, (2005)
[6] Kuban D.A., Tucker S.L., Dong L., Et al., Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, pp. 67-74, (2008)
[7] Zelefsky M.J., Yamada Y., Fuks Z., Et al., Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes, Int J Radiat Oncol Biol Phys, 71, pp. 1028-1033, (2008)
[8] Kupelian P.A., Ciezki J., Reddy C.A., Et al., Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer, Int J Radiat Oncol Biol Phys, 71, pp. 16-22, (2008)
[9] Morris W.J., Tyldesley S., Rodda S., Et al., Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer, Int J Radiat Oncol Biol Phys, 98, pp. 275-285, (2017)
[10] Zheng J., Bachand F., Halperin R., Et al., 70: after ASCENDE-RT: outcomes of androgen deprivation, external beam radiation and LDR brachytherapy boost for high-tier intermediate and high risk prostate cancer treated at BC cancer Kelowna, Radiother Oncol, 163, pp. S32-S33, (2021)

← 1 2 3 4 →